JP2006527226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527226A5 JP2006527226A5 JP2006515869A JP2006515869A JP2006527226A5 JP 2006527226 A5 JP2006527226 A5 JP 2006527226A5 JP 2006515869 A JP2006515869 A JP 2006515869A JP 2006515869 A JP2006515869 A JP 2006515869A JP 2006527226 A5 JP2006527226 A5 JP 2006527226A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- aryl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 108
- -1 Dioxolyl Chemical group 0.000 claims 89
- 229910052739 hydrogen Inorganic materials 0.000 claims 58
- 239000001257 hydrogen Substances 0.000 claims 58
- 229910052736 halogen Inorganic materials 0.000 claims 55
- 125000001424 substituent group Chemical group 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 48
- 150000002367 halogens Chemical class 0.000 claims 45
- 125000001072 heteroaryl group Chemical group 0.000 claims 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 36
- 150000002431 hydrogen Chemical class 0.000 claims 35
- 125000004122 cyclic group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000004043 oxo group Chemical group O=* 0.000 claims 24
- 125000001544 thienyl group Chemical group 0.000 claims 20
- 125000002541 furyl group Chemical group 0.000 claims 18
- 125000004076 pyridyl group Chemical group 0.000 claims 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 150000002825 nitriles Chemical class 0.000 claims 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 125000001624 naphthyl group Chemical group 0.000 claims 15
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000004104 aryloxy group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 10
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 10
- 125000002757 morpholinyl group Chemical group 0.000 claims 10
- 125000003386 piperidinyl group Chemical group 0.000 claims 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 10
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 10
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 9
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000004414 alkyl thio group Chemical group 0.000 claims 8
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 8
- 150000002430 hydrocarbons Chemical group 0.000 claims 8
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 8
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 8
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 8
- 125000003725 azepanyl group Chemical group 0.000 claims 7
- 125000002393 azetidinyl group Chemical group 0.000 claims 7
- 239000004305 biphenyl Substances 0.000 claims 7
- 235000010290 biphenyl Nutrition 0.000 claims 7
- 125000001246 bromo group Chemical group Br* 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 125000005961 oxazepanyl group Chemical group 0.000 claims 7
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 7
- 125000004193 piperazinyl group Chemical group 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 7
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 7
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 7
- 125000000335 thiazolyl group Chemical group 0.000 claims 7
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 239000003270 steroid hormone Substances 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 5
- 125000001041 indolyl group Chemical group 0.000 claims 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000005251 aryl acyl group Chemical group 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000005959 diazepanyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001680 trimethoxyphenyl group Chemical group 0.000 claims 4
- 201000004384 Alopecia Diseases 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000005110 aryl thio group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- JZGZKRJVTIRPOK-UHFFFAOYSA-N ethyl thiophene-2-carboxylate Chemical compound CCOC(=O)C1=CC=CS1 JZGZKRJVTIRPOK-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 201000007954 uterine fibroid Diseases 0.000 claims 3
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 206010039792 Seborrhoea Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010046788 Uterine haemorrhage Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 206010068168 androgenetic alopecia Diseases 0.000 claims 2
- 201000002996 androgenic alopecia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 201000009274 endometriosis of uterus Diseases 0.000 claims 2
- 239000002583 male contraceptive agent Substances 0.000 claims 2
- 208000007106 menorrhagia Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- 230000021595 spermatogenesis Effects 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical group O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 1
- XHHYIAWXOGUEII-UHFFFAOYSA-N 2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(2-methylpropyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC(C)C)=C1Br XHHYIAWXOGUEII-UHFFFAOYSA-N 0.000 claims 1
- DRJKOQOGSXDPKO-UHFFFAOYSA-N 2-(2-chloro-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(2-methylbutyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1Cl DRJKOQOGSXDPKO-UHFFFAOYSA-N 0.000 claims 1
- QCKAVYPIXVSRIP-UHFFFAOYSA-N 2-(2-chloro-3,4,5-trimethoxyphenyl)-8-hydroxy-3-(oxolan-2-ylmethyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC2OCCC2)=C1Cl QCKAVYPIXVSRIP-UHFFFAOYSA-N 0.000 claims 1
- BLRNHMUGGSGEFC-UHFFFAOYSA-N 2-(8-hydroxy-4-oxo-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-3-yl)ethyl thiophene-2-carboxylate Chemical compound OC1=CC=CC(C=2C(=O)N3CCOC(=O)C=4SC=CC=4)=C1SC=2N=C3C1=CC=CS1 BLRNHMUGGSGEFC-UHFFFAOYSA-N 0.000 claims 1
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- DCLCVMZXAZXDIA-UHFFFAOYSA-N 3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-propyl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound CCCC1=NC=2SC3=C(O)C=CC=C3C=2C(=O)N1CC1=CC=C(Br)O1 DCLCVMZXAZXDIA-UHFFFAOYSA-N 0.000 claims 1
- BYLUGBTVNKWOOP-UHFFFAOYSA-N 3-benzyl-2-(2-chloro-3,4,5-trimethoxyphenyl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=CC=CC(O)=C4SC=3N=2)CC=2C=CC=CC=2)=C1Cl BYLUGBTVNKWOOP-UHFFFAOYSA-N 0.000 claims 1
- IHFCTBYGNJBHLU-UHFFFAOYSA-N 3-benzyl-2-(4-methoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound C1=CC(OC)=CC=C1C(N(C1=O)CC=2C=CC=CC=2)=NC2=C1C1=CC=C(C=O)C=C1S2 IHFCTBYGNJBHLU-UHFFFAOYSA-N 0.000 claims 1
- PLMIWUYUHDKIOU-UHFFFAOYSA-N 3-benzyl-8-ethylsulfanyl-2-(4-methoxyphenyl)-4-oxo-5,6-dihydro-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound CCSC1=C(C=O)CCC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=C(OC)C=C1 PLMIWUYUHDKIOU-UHFFFAOYSA-N 0.000 claims 1
- GOBGXFNVRDORKE-UHFFFAOYSA-N 3-benzyl-8-ethylsulfanyl-2-(4-methoxyphenyl)-4-oxo-[1]benzothiolo[2,3-d]pyrimidine-7-carbaldehyde Chemical compound CCSC1=C(C=O)C=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=C(OC)C=C1 GOBGXFNVRDORKE-UHFFFAOYSA-N 0.000 claims 1
- XPTDTOFYTCYHSF-UHFFFAOYSA-N 3-benzyl-8-hydroxy-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound OC1=CC=CC(C=2C(=O)N3CC=4C=CC=CC=4)=C1SC=2N=C3C1=CC=CS1 XPTDTOFYTCYHSF-UHFFFAOYSA-N 0.000 claims 1
- XQSDTRVRYXPNAZ-UHFFFAOYSA-N 3-butyl-2-(2,4-difluorophenyl)-8-hydroxy-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCCC)C=1C1=CC=C(F)C=C1F XQSDTRVRYXPNAZ-UHFFFAOYSA-N 0.000 claims 1
- CMIPVAHJRMGCEL-UHFFFAOYSA-N 3-butyl-8-hydroxy-2-(2-methoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCCC)C=1C1=CC=CC=C1OC CMIPVAHJRMGCEL-UHFFFAOYSA-N 0.000 claims 1
- HHBJKZCQWKMHNL-UHFFFAOYSA-N 3-butyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CCCC)C=1C1=CC(OC)=C(OC)C(OC)=C1 HHBJKZCQWKMHNL-UHFFFAOYSA-N 0.000 claims 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims 1
- FVCXLTHFQRFWJY-UHFFFAOYSA-N 5-bromo-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound COC1=C(OC)C(OC)=CC(C=2N(C(=O)C=3C4=C(C(CCC4Br)=O)SC=3N=2)CC(C)C)=C1 FVCXLTHFQRFWJY-UHFFFAOYSA-N 0.000 claims 1
- FBFTVBPTKNXUJZ-UHFFFAOYSA-N 7-bromo-3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5h-[1]benzothiolo[2,3-d]pyrimidine-4,8-dione Chemical compound N=1C=2SC(C(C(Br)CC3)=O)=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1 FBFTVBPTKNXUJZ-UHFFFAOYSA-N 0.000 claims 1
- RSKOJBUMOCXXJN-UHFFFAOYSA-N 7-bromo-8-hydroxy-3-(2-methoxyethyl)-2-thiophen-2-yl-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C(Br)=CC=C3C=2C(=O)N(CCOC)C=1C1=CC=CS1 RSKOJBUMOCXXJN-UHFFFAOYSA-N 0.000 claims 1
- IERNYVIIHPXXCC-UHFFFAOYSA-N 8-hydroxy-3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound N=1C=2SC3=C(O)C=CC=C3C=2C(=O)N(CC(C)CC)C=1C1=CC(OC)=C(OC)C(OC)=C1 IERNYVIIHPXXCC-UHFFFAOYSA-N 0.000 claims 1
- 208000005641 Adenomyosis Diseases 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 claims 1
- 206010014756 Endometrial hypertrophy Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010048469 Kidney enlargement Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- IWWPVLAMLDKZCY-UHFFFAOYSA-N [3-[(5-bromofuran-2-yl)methyl]-4-oxo-2-propyl-[1]benzothiolo[2,3-d]pyrimidin-8-yl] acetate Chemical compound CCCC1=NC=2SC3=C(OC(C)=O)C=CC=C3C=2C(=O)N1CC1=CC=C(Br)O1 IWWPVLAMLDKZCY-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000950 dibromo group Chemical group Br* 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001788 irregular Effects 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- DRTQHLFDZIQYNT-UHFFFAOYSA-N methyl 2-(3-benzyl-7-tert-butyl-4-oxo-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl)acetate Chemical compound COC(=O)CC1=NC=2SC=3CC(C(C)(C)C)CCC=3C=2C(=O)N1CC1=CC=CC=C1 DRTQHLFDZIQYNT-UHFFFAOYSA-N 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims 1
- 0 CC(C(*)C1*)C(*)C(*2)=C1C1=C2N=C(*)N(*)C1=O Chemical compound CC(C(*)C1*)C(*)C(*2)=C1C1=C2N=C(*)N(*)C1=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47704703P | 2003-06-10 | 2003-06-10 | |
| PCT/EP2004/006230 WO2005032527A2 (en) | 2003-06-10 | 2004-06-09 | Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006527226A JP2006527226A (ja) | 2006-11-30 |
| JP2006527226A5 true JP2006527226A5 (https=) | 2007-07-19 |
| JP4605800B2 JP4605800B2 (ja) | 2011-01-05 |
Family
ID=34421462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515869A Expired - Fee Related JP4605800B2 (ja) | 2003-06-10 | 2004-06-09 | 新規化合物および治療におけるその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7465739B2 (https=) |
| EP (1) | EP1635839B1 (https=) |
| JP (1) | JP4605800B2 (https=) |
| KR (1) | KR20060054189A (https=) |
| CN (1) | CN1791412A (https=) |
| AR (1) | AR044650A1 (https=) |
| AT (1) | ATE479437T1 (https=) |
| AU (1) | AU2004277311B8 (https=) |
| BR (1) | BRPI0411295A (https=) |
| CA (1) | CA2527617A1 (https=) |
| DE (1) | DE602004028934D1 (https=) |
| DK (1) | DK1635839T3 (https=) |
| ES (2) | ES2352552T3 (https=) |
| IL (1) | IL172316A0 (https=) |
| MX (1) | MXPA05012745A (https=) |
| NO (1) | NO20060123L (https=) |
| PL (1) | PL1635839T3 (https=) |
| PT (1) | PT1635839E (https=) |
| RU (1) | RU2412190C2 (https=) |
| SA (1) | SA04250159B1 (https=) |
| SI (1) | SI1635839T1 (https=) |
| TW (1) | TWI349551B (https=) |
| WO (1) | WO2005032527A2 (https=) |
| ZA (1) | ZA200508296B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| JP2007536239A (ja) * | 2004-05-06 | 2007-12-13 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
| WO2006044826A2 (en) * | 2004-10-20 | 2006-04-27 | Compass Pharmaceuticals Llc | Thiophens and their use as anti-tumor agents |
| PL1828197T3 (pl) * | 2004-12-13 | 2009-11-30 | Solvay Pharm Gmbh | Nowe podstawione pochodne tiofenopirymidynonu jako inhibitory dehydrogenazy 17ß-hydroksysteroidowej |
| FR2904000A1 (fr) * | 2006-07-19 | 2008-01-25 | Galderma Res & Dev S N C Snc | Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee |
| FR2904318B1 (fr) * | 2006-07-27 | 2011-02-25 | Scras | Derives de pyrimidinone et leur utilisation comme medicament |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| DE102007015169A1 (de) * | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| WO2009001214A2 (en) * | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
| JP2012513481A (ja) * | 2008-12-23 | 2012-06-14 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ネクロトーシスの小分子阻害剤 |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| WO2012119605A1 (en) * | 2011-03-10 | 2012-09-13 | Akar Yahya Ahmed Abdellhafeez Salem | New disperse dye with potent anticancer activity |
| TW201520219A (zh) * | 2013-03-12 | 2015-06-01 | Lilly Co Eli | 咪唑並吡啶化合物 |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6556125B2 (ja) | 2013-06-25 | 2019-08-07 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体 |
| JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| EP3089969A2 (en) | 2014-01-03 | 2016-11-09 | Elexopharm GmbH | Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2 |
| WO2015114663A1 (en) | 2014-01-30 | 2015-08-06 | Council Of Scientific & Industrial Research | Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties |
| GB201419102D0 (en) * | 2014-10-27 | 2014-12-10 | Imp Innovations Ltd | Novel compounds |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| US20180312493A1 (en) * | 2015-11-04 | 2018-11-01 | Simon Fraser University | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor |
| HRP20240679T1 (hr) | 2017-06-08 | 2024-08-16 | Organon R&D Finland Ltd | 17-oksimi 15.beta.-[3-propanamido]-supstituiranih etera-1,3,5(10)-trien-17-ona za uporabu u inhibiciji 17.beta.-hidroksisteroid dehidrogenaza |
| CN109503572B (zh) * | 2017-09-15 | 2021-10-08 | 上海交通大学 | 一种合成吲哚喹啉类化合物的方法 |
| JP7417608B2 (ja) | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 |
| EP4514805A4 (en) * | 2022-04-28 | 2026-01-21 | Enanta Pharm Inc | TYPE 13 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS CONTAINING PYRIMIDINONE |
| US20250154163A1 (en) * | 2023-10-26 | 2025-05-15 | Enanta Pharmaceuticals, Inc. | Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4742271B1 (https=) * | 1968-06-20 | 1972-10-25 | ||
| US3775027A (en) | 1971-10-01 | 1973-11-27 | Gray Manuf Co Inc | Two-speed pump |
| JPS62132884A (ja) | 1985-12-05 | 1987-06-16 | Mitsubishi Chem Ind Ltd | ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体 |
| WO1989008113A1 (en) | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF |
| US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| JP3783810B2 (ja) | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
| JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
| WO1999012540A1 (en) | 1997-09-11 | 1999-03-18 | Snow Brand Milk Products Co., Ltd. | Remedies for hormone-dependent diseases |
| HUP0101809A3 (en) | 1998-03-11 | 2002-07-29 | Endorech Inc Sainte Foy | Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use |
| WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| US6784167B2 (en) | 2000-09-29 | 2004-08-31 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-II inhibitors |
| WO2003017973A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method |
| PE20030703A1 (es) | 2001-09-06 | 2003-08-21 | Schering Corp | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 |
| US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
-
2004
- 2004-06-07 US US10/861,907 patent/US7465739B2/en not_active Expired - Fee Related
- 2004-06-08 AR ARP040101983A patent/AR044650A1/es not_active Application Discontinuation
- 2004-06-08 TW TW093116411A patent/TWI349551B/zh not_active IP Right Cessation
- 2004-06-09 BR BRPI0411295-4A patent/BRPI0411295A/pt not_active IP Right Cessation
- 2004-06-09 WO PCT/EP2004/006230 patent/WO2005032527A2/en not_active Ceased
- 2004-06-09 KR KR1020057022958A patent/KR20060054189A/ko not_active Abandoned
- 2004-06-09 AT AT04803089T patent/ATE479437T1/de active
- 2004-06-09 RU RU2006100033/04A patent/RU2412190C2/ru not_active IP Right Cessation
- 2004-06-09 CN CNA200480013515XA patent/CN1791412A/zh active Pending
- 2004-06-09 ES ES04803089T patent/ES2352552T3/es not_active Expired - Lifetime
- 2004-06-09 JP JP2006515869A patent/JP4605800B2/ja not_active Expired - Fee Related
- 2004-06-09 CA CA002527617A patent/CA2527617A1/en not_active Abandoned
- 2004-06-09 PT PT04803089T patent/PT1635839E/pt unknown
- 2004-06-09 SI SI200431535T patent/SI1635839T1/sl unknown
- 2004-06-09 ZA ZA200508296A patent/ZA200508296B/xx unknown
- 2004-06-09 MX MXPA05012745A patent/MXPA05012745A/es active IP Right Grant
- 2004-06-09 DE DE602004028934T patent/DE602004028934D1/de not_active Expired - Lifetime
- 2004-06-09 PL PL04803089T patent/PL1635839T3/pl unknown
- 2004-06-09 EP EP04803089A patent/EP1635839B1/en not_active Expired - Lifetime
- 2004-06-09 AU AU2004277311A patent/AU2004277311B8/en not_active Ceased
- 2004-06-09 DK DK04803089.4T patent/DK1635839T3/da active
- 2004-06-12 SA SA4250159A patent/SA04250159B1/ar unknown
- 2004-11-03 ES ES04805369T patent/ES2352554T3/es not_active Expired - Lifetime
-
2005
- 2005-12-01 IL IL172316A patent/IL172316A0/en unknown
-
2006
- 2006-01-09 NO NO20060123A patent/NO20060123L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006527226A5 (https=) | ||
| RU2412190C2 (ru) | Новые соединения и их применение в терапии | |
| US12049461B2 (en) | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | |
| US8338435B2 (en) | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections | |
| US8673929B2 (en) | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | |
| CA2514407A1 (en) | Thienopyrimidine compounds and use thereof | |
| JP2006527227A5 (https=) | ||
| WO2005092896A1 (en) | Compound for inhibiting tyrosine kinase activity of ddr2 protein | |
| WO1998053819A1 (en) | Therapeutic agent for erection failure | |
| CA2672591A1 (en) | Treating agent of uropathy | |
| RU2007117770A (ru) | Дизамещенные пиразолобензадепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
| CN101133056A (zh) | 抗肿瘤化合物 | |
| JP2005505535A5 (https=) | ||
| JP2007519753A5 (https=) | ||
| JP2016164177A5 (https=) | ||
| CA2612176C (en) | Dihydrothieno[2,3-d]pyramidine-6-carboxylic acid derivatives as pde9 inhibitors | |
| CN1946395B (zh) | 用作激酶抑制剂的1H-噻吩并[2,3-c]吡唑衍生物 | |
| CN101679272A (zh) | 作为腺苷a3受体配体的三唑并[1,5-a]喹啉类 | |
| JP2008521855A (ja) | 新規ピリドチエノピリミジン誘導体 | |
| JP2008521854A (ja) | 新規ピリドチエノピリミジン誘導体 | |
| JP2003292492A5 (https=) | ||
| ES2327240T3 (es) | Nuevos derivados sustituidos de tiofempirimidinona en calidad de inhibidores de 17beta-hidroxiesteroide deshidrogenasa. | |
| RU2007126552A (ru) | НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ | |
| RU2017133093A (ru) | Кристаллические формы соединения пирролопиридина | |
| KR20240136392A (ko) | Malt-1 억제제로서의 치환된 바이사이클릭 헤테로사이클 |